Marco Ritelli Selected Research

Marco Ritelli Research Topics

Disease

8	Ehlers-Danlos Syndrome (Syndrome, Ehlers-Danlos) 12/2022 - 10/2012
5	Type IV Ehlers-Danlos Syndrome 01/2024 - 10/2012
3	Loeys-Dietz Syndrome 01/2023 - 10/2019
2	Cicatrix (Scar) 10/2019 - 09/2012
2	Inflammation (Inflammations) 03/2018 - 04/2005
2	Hemorrhage 01/2018 - 09/2012
2	Acute Kidney Injury (Acute Renal Failure) 01/2016 - 01/2014
2	Nephrolithiasis 01/2016 - 01/2014
2	Renal hypouricemia 01/2016 - 01/2014
2	Prolapse 05/2013 - 09/2012
1	Keratoacanthoma familial 01/2023
1	Hereditary alpha-tryptasemia syndrome 04/2022
1	Hypertension (High Blood Pressure) 10/2021
1	Osteogenesis Imperfecta (Lobstein Disease) 01/2020
1	Chronic Mucocutaneous Candidiasis 11/2019
1	Cerebral Infarction 10/2019
1	Aortic Dissection 10/2019
1	Gerodermia osteodysplastica 01/2019
1	Wounds and Injuries (Trauma) 01/2019
1	Rupture 01/2018
1	Ischemic Stroke 01/2018
1	Cerebral Hemorrhage 01/2018
1	Cutis Laxa 10/2017
1	Aortic Rupture 06/2016
1	Familial Thoracic 1 Aortic Aneurysm 06/2016
1	Stroke (Strokes) 01/2016
1	Spondyloepimetaphyseal Dysplasia With Joint Laxity 03/2015
1	Hematoma 02/2014
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2014
1	Osteoarthritis 05/2013
1	Visceral Prolapse (Visceroptosis) 05/2013
1	Ascending Aorta Aneurysm 05/2013
1	Pathologic Processes 10/2012
1	Venous Thrombosis (Deep-Vein Thrombosis) 09/2012
1	Blood Vessel Dissection 12/2011
1	Hepatocellular Carcinoma (Hepatoma) 06/2007
1	Neoplasms (Cancer) 06/2007
1	Carcinoma (Carcinomatosis) 06/2007
1	Neuroblastoma 06/2007
1	Autoimmune Diseases (Autoimmune Disease) 04/2005

Drug/Important Bio-Agent (IBA)

4	Transforming Growth Factor-beta Type I ReceptorIBA 01/2023 - 12/2011
4	IntegrinsIBA 01/2019 - 06/2007
4	Fibronectins (Fibronectin)IBA 01/2019 - 06/2007
3	Collagen Type III (Type III Collagen)IBA 01/2024 - 10/2012
3	CollagenIBA 05/2022 - 10/2012
2	Glycine (Aminoacetic Acid)FDA LinkGeneric 05/2022 - 01/2018
2	Collagen Type V (Type V Collagen)IBA 10/2020 - 01/2019
2	Transforming Growth Factor-beta Type II ReceptorIBA 11/2019 - 12/2011
2	AnticoagulantsIBA 01/2018 - 02/2014
2	Uric Acid (Urate)IBA 01/2016 - 01/2014
1	Celiprolol (ST1396)IBA 12/2023
1	LigandsIBA 01/2023
1	Biomarkers (Surrogate Marker)IBA 12/2022
1	RNA (Ribonucleic Acid)IBA 12/2022
1	Lysine (L-Lysine)FDA Link 05/2022
1	Glutamic Acid (Glutamate)FDA Link 05/2022
1	Tryptases (Tryptase)IBA 04/2022
1	Doxycycline (Periostat)FDA LinkGeneric 11/2021
1	Matrix Metalloproteinases (MMPs)IBA 11/2021
1	ORALIT (ORS)IBA 10/2021
1	ProteomeIBA 01/2021
1	Collagen Type I (Type I Collagen)IBA 10/2020
1	alpha2 Subunit Collagen Type IIBA 01/2020
1	beta-cyclodextrin tetradecasulfate (CTDS)IBA 11/2019
1	tenascin XIBA 10/2019
1	Transforming Growth Factor beta (TGF-beta)IBA 10/2019
1	Glucuronosyltransferase (UDP Glucuronosyltransferase)IBA 01/2019
1	GalactosyltransferasesIBA 01/2019
1	Proteins (Proteins, Gene)FDA Link 01/2019
1	Warfarin (Coumadin)FDA LinkGeneric 01/2018
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2018
1	CholesterolIBA 01/2016
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2016
1	Proteoglycans (Proteoglycan)IBA 03/2015
1	galactosylxylosylprotein 3-beta-galactosyltransferaseIBA 03/2015
1	GlycosaminoglycansIBA 03/2015
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 10/2012
1	Transforming Growth Factors (Transforming Growth Factor)IBA 12/2011
1	3-hydroxy-5-estrane-17-carbonitrile (ACN)IBA 06/2007
1	Amino Acids FDA Link 06/2007
1	Peptides (Polypeptides)IBA 06/2007
1	Interferon-alpha (Interferon Alfa)IBA 04/2005
1	EndotoxinsIBA 04/2005

Therapy/Procedure

3	Therapeutics 12/2023 - 10/2019
1	Thrombectomy 10/2019
1	Semiconductors 10/2017
1	Endovascular Aneurysm Repair 06/2016
1	Gastropexy 05/2013
1	Operative Surgical Procedures 05/2013
1	Gastroenterostomy 05/2013
1	Gastrectomy 05/2013
1	Episiotomy 09/2012